Circadian Technologies Limited (CIR.AX) Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
1/9/2012 10:19:05 AM
More...
|
Circadian Technologies Limited (CIR.AX) Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
10/31/2011 11:22:35 AM
More...
|
Circadian Technologies Limited (CIR.AX) Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
9/30/2011 10:16:24 AM
More...
|
Circadian Technologies Limited (CIR.AX) Release: VGX-100 Identified as Potential New Therapy for Dry Eye Disease
9/13/2011 11:38:21 AM
More...
|
Merriman Capital Announces Sponsorship of Circadian Technologies Limited (CIR.AX) on OTCQX
6/14/2011 9:00:25 AM
More...
|
Circadian Technologies Limited (CIR.AX) Release: VEGF-C and VEGF-D Identified as Biomarkers for Avastin Resistance in Colorectal Cancer Patients
6/7/2011 8:23:13 AM
More...
|
Circadian Technologies Limited (CIR.AX)'s VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer
4/6/2011 7:35:03 AM
More...
|
Circadian Technologies Limited (CIR.AX)'s Partner ImClone Systems Corporation (IMCL) Commences First Phase 1 Clinical Trial of VEGFR-3 Antibody IMC-3C5
4/6/2011 7:32:51 AM
More...
|
Circadian Technologies Limited (CIR.AX) Launches First Diagnostic for LAM Lung Disease With U.S. Partner
2/2/2011 7:58:50 AM
More...
|
Circadian Technologies Limited (CIR.AX) Launches First Diagnostic for LAM Lung Disease With U.S. Partner
2/2/2011 7:09:18 AM
More...
|
|